#USA #Waltham #Syndax Pharmaceuticals #avodart #Revuforj

Syndax Pharmaceuticals to Participate in Citi 2024 Global Healthcare Conference

Syndax Pharmaceuticals, a leading biopharmaceutical company recognized for its commitment to advancing cancer treatments, is set to participate in the highly anticipated Citi 2024 Global Healthcare Conference. The conference will feature prominent discussions and presentations from industry leaders and will take place on December 5, 2024, with Syndax's CEO, Michael A. Metzger, taking the stage for a panel discussion on "Novel Mechanisms in Oncology." This presents a prime opportunity for Syndax to showcase their cutting-edge research and development in the oncology space.

Event Details

During the panel discussion, attendees can expect insights into the latest advancements in cancer therapies, particularly those being developed by Syndax. The company is currently making waves with an innovative lineup, including its FDA-approved menin inhibitor, Revuforj® (revumenib), and the monoclonal antibody Niktimvo™ (axatilimab-csfr) which targets the colony stimulating factor 1 receptor. These therapies are positioned at the forefront of oncology treatment, aiming to enhance patient outcomes and redefine cancer care as we know it.

The conference is scheduled to start at 11:00 a.m. ET, and a live webcast will be available on Syndax's official investor relations page at www.syndax.com. Following the event, a replay will also be accessible for those who wish to catch up on the discussion.

About Syndax Pharmaceuticals

Syndax is a commercial-stage biopharmaceutical firm grounded in a mission to reimagine cancer care. Their dedication is evident through their extensive pipeline of therapies designed to meet unmet clinical needs across different cancer types.

Lead development programs include Revuforj®, which is making headway in treating adult and pediatric patients dealing with relapsed or refractory acute leukemia stemming from KMT2A translocations. In addition, Niktimvo™, which has shown promise in targeting myeloid-derived suppressor cells, has also received FDA approval. These developments signal a new era of treatment possibilities that may result in better survival rates and quality of life for patients.

The company's ongoing commitment to expanding its clinical trials further emphasizes its proactive approach in battling cancer from multiple fronts. With a wide array of investigational therapies in the pipeline, Syndax is strategically positioned to transform the landscape of oncology.

Looking Ahead

As Syndax Pharmaceuticals shares its expertise and insights on a global platform, the emphasis remains steadfast on collaboration and innovation within the sector. The Citi 2024 Global Healthcare Conference not only highlights the strides being made by Syndax but also contributes to the broader discourse on the future of cancer treatment.

For further updates, readers are encouraged to follow Syndax on their social media channels, including X (formerly known as Twitter) and LinkedIn, for the latest developments and insights into their pipeline enhancements and clinical trial results.

As the healthcare community looks towards innovative solutions in battling cancer, Syndax Pharmaceuticals stands as a beacon of hope, promising a brighter and healthier future for patients around the world.